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Abstract
Background: Eukaryotic initiation factor 4E (eIF4E) is essential for cap-dependent initiation of
translation. Cell proliferation is associated with increased activity of eIF4E and elevated expression
of eIF4E leads to tumorigenic transformation. Many tumors express very high levels of eIF4E and
this may be a critical factor in progression of the disease. In contrast, overexpression of 4EBP, an
inhibitor of eIF4E, leads to cell cycle arrest and phenotypic reversion of some transformed cells.
Results: A constitutively active form of 4EBP-1 was inducibly expressed in the human breast
cancer cell line MCF7. Induction of constitutively active 4EBP-1 led to cell cycle arrest. This was
not associated with a general inhibition of protein synthesis but rather with changes in specific cell
cycle regulatory proteins. Cyclin D1 was downregulated while levels of the CDK inhibitor p27Kip1
were increased. The levels of cyclin E and CDK2 were unaffected but the activity of CDK2 was
significantly reduced due to increased association with p27Kip1. The increase in p27Kip1 did not
reflect changes in p27Kip1 mRNA or degradation rates. Rather, it was associated with enhanced
synthesis of the protein, even though 4EBP-1 is expected to inhibit translation. This could be
explained, at least in part, by the ability of the p27Kip1 5'-UTR to mediate cap-independent
translation, which was also enhanced by expression of constitutively active 4EBP-1.
Conclusions: Expression of active 4EBP-1 in MCF7 leads to cell cycle arrest which is associated
with downregulation of cyclin D1 and upregulation of p27Kip1. Upregulation of p27Kip1reflects
increased synthesis which corresponds to enhanced cap-independent translation through the 5'-
UTR of the p27Kip1 mRNA.
Background
Most eukaryotic mRNAs are translated through a cap-de-
pendent mechanism of initiation. In this process, eIF4E,
which functions by binding the 7-methylguanosine cap, is
the rate-limiting factor due to its low abundance [1,2]. In
normal cells, elevated eIF4E activity is associated with pro-
liferation and is regulated by multiple mechanisms. eIF4E
gene transcription is enhanced in response to mitogenic
stimulation and may be mediated by c-myc [3]. Phospho-
rylation of eIF4E by the protein kinase Mnk1 increases its
affinity for the cap, and thus increases cap-dependent ini-
tiation of translation [4–6]. An inhibitor of eIF4E, 4E
binding protein (4EBP), is also regulated by phosphoryla-
tion. Phosphorylation of 4EBP disrupts its ability to bind
eIF4E, freeing eIF4E to bind eIF4G, which functions to re-
cruit additional components of the initiation complex
[7,8]. The net result is that phosphorylation of 4EBP en-
hances cap-dependent translation initiation. 4EBP
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phosphorylation is thought to be mediated by mammali-
an target of rapamycin (mTOR) in mitogen stimulated
cells [9–11].
Numerous studies have implicated eIF4E in formation
and progression of tumors. Overexpression of eIF4E leads
to deregulated growth and malignant transformation of a
variety of cultured cell lines [12–14]. Moreover, elevated
levels of eIF4E are commonly found in solid tumors, espe-
cially in breast, colon, and head and neck tumors [15].
Clinical studies indicate that eIF4E gene amplification
and protein overexpression is associated with malignant
progression in these tumors [16]. High eIF4E levels are
also associated with a higher rate of cancer recurrence and
cancer-related death [17]. In contrast to eIF4E, overexpres-
sion of 4EBP inhibits cell proliferation [18] and 4EBP-1
expression levels are inversely correlated with the progres-
sion of certain types of tumors [19].
The findings summarized above indicate that elevated
eIF4E activity plays a fundamental role in cancer forma-
tion and progression and suggest the possibility that eIF4E
could be exploited as a therapeutic target. This is support-
ed by several recent investigations. Inhibiting the expres-
sion of eIF4E by expressing antisense RNA reverses ras-
mediated transformation of cultured cells as indicated by
decreased efficiency of growth in soft agar and tumor for-
mation in nude mice [20]. Similarly, antisense-mediated
reduction of eIF4E in breast cancer cells inhibits both their
tumorigenic and angiogenic properties [21]. On the other
hand, overexpression of 4EBP reverses transformation
mediated by v-src [18].
Rapamycin and its analogs are potent inhibitors of mTOR
and lead to cell cycle arrest. Thus there is interest in using
this class of inhibitors for chemotherapeutic treatment of
cancer and several phase I trials have been carried out
[22]. Treatment of mammalian cells with rapamycin leads
to dephosphorylation and activation of 4EBP, which in
turn binds to and inhibits eIF4E. However, several other
targets downstream of mTOR are also affected by rapamy-
cin. These include effects on other translational control
proteins including p70 S6 kinase (p70S6K), eIF4G, eIF4B,
and eEF2 (reviewed in [23]). At present neither the targets
that are essential for inhibition of cell proliferation by ra-
pamycin nor the mechanism by which these targets medi-
ate cell cycle arrest are completely understood.
In the present study an MCF7 breast cancer cell line was
developed which can be induced to express a mutant form
of 4EBP-1 in which five amino acids that are targets for
phosphorylation have been changed to alanines [24].
Since the protein cannot be inactivated by phosphoryla-
tion it constitutively binds to and inhibits eIF4E. Thus ex-
pression of the mutant mimics the effects of rapamycin on
4EBP but does not affect the other targets of mTOR. In-
duction of the constitutively active 4EBP-1 leads to cell cy-
cle arrest which correlates with loss of cyclin D1
expression and increased levels of the cyclin dependent ki-
nase inhibitor p27Kip1. The increase in p27Kip1 is mediat-
ed, at least in part, by enhanced synthesis of the protein
and corresponds to activation of the p27Kip1 mRNA 5'-un-
translated region (UTR) and its ability to mediate cap-in-
dependent initiation of translation.
Results
Expression of constitutively active 4EBP-1 inhibits the pro-
liferation of MCF7 cells
To test the effect of 4EBP-1 on the proliferation of human
breast cancer cells, an expression vector encoding the con-
stitutively active 4EBP-1 mutant (4EBP-1-5A) was stably
transfected into MCF7 cells. The 4EBP-1-5A cDNA was
placed under the control of a promoter that is responsive
to the insect hormone ponasterone A (pon A), an ecdys-
one analog. In the absence of pon A an ecdysone receptor/
VP16 fusion protein actively represses the promoter lead-
ing to very low basal levels of expression. In the presence
of pon A the ecdysone receptor recruits coactivators that
lead to elevated expression. The stably transfected MCF7
line (MCF7-4EBP-1-5A) was treated with pon A and at
various times cells were harvested for analysis of 4EBP-1
expression by Western blotting (Fig. 1A). Several forms of
4EBP-1 are present in the stably transfected MCF7 cells.
The slower migrating bands represent endogenous 4EBP-
1 that is phosphorylated at various sites. The fastest mi-
grating band corresponds to hypophosphorylated 4EBP-
1. Treatment with pon A leads to a rapid increase in the in-
tensity of the fastest migrating band, which corresponds
to the 4EBP-1-5A mutated form of the protein which can-
not be phosphorylated. In cells treated with pon A, the
fastest migrating form of 4EBP-1 is the predominant band
at all time points. Expression of this form of 4EBP-1 con-
tinues to increase for at least five days after treatment with
pon A. In the control cells, which were not treated with
pon A, phosphorylated, inactive 4EBP-1 is the predomi-
nant form of the protein (Fig. 1A). Treatment of untrans-
fected MCF7 cells with pon A had no effect on expression
or phosphorylation status of 4EBP-1 (data not shown).
The expressed 4EBP-1-5A protein is active as determined
by a large increase in the amount of 4EBP-1 bound to
eIF4E in pon A treated MCF7-4EBP-1-5A cells (Fig. 1B).
Expression of constitutively active 4EBP-1, through inhi-
bition of eIF4E activity, would be expected to slow the rate
of proliferation of MCF7 cells. To test this, the growth of
MCF7-4EBP-1-5A breast cancer cells was determined by
counting cell number in cultures treated with or without
pon A (Fig. 1C). In the absence of pon A, the cells contin-
ued to proliferate for at least five days. However, induc-
tion of 4EBP-1-5A by the addition of pon A almostCancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/2
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completely blocked cell proliferation. There was no indi-
cation of cell death in the pon A treated cultures and pon
A had no effect on the untransfected parental MCF7 cell
line (Fig. 1C). These results indicate that expression of
constitutively active 4EBP-1 leads to cell cycle arrest of
MCF7 cells.
Expression of 4EBP-1-5A results in enhanced p27Kip1 ex-
pression and downregulation of cyclin D1
Elevated levels of eIF4E are associated with tumorigenic
transformation and enhanced expression of specific cell
cycle regulatory proteins such as cyclin D1. Expression of
constitutively active 4EBP-1 should lead to a global de-
crease in cap-dependent translation which could lead to
cell cycle arrest. However, it is also possible that constitu-
tively active 4EBP-1 inhibits proliferation through specific
effects on cell cycle regulatory proteins. Therefore, a
number of G1 cell cycle regulatory molecules were exam-
ined in MCF7-4EBP-1-5A cells that had been treated with
Figure 1
Expression of 4EBP-1-5A inhibits proliferation of 
MCF-7 cells. (A) MCF7-4EBP-1-5A cells were treated with 
or without pon A for up to 5 days as indicated. Cell extracts 
representing 2 × 105 cells were used for Western blotting 
with anti-4EBP-1. The lower band (arrow) represents endog-
enous, hypophosphorylated 4EBP-1 and 4EBP-1-5A induced 
by pon A. (B) MCF7-4EBP-1-5A cells were cultured in the 
presence or absence of pon A for 2 days. Cell extracts were 
prepared and equal amounts of protein were incubated with 
7-methyl-GTP-Sepharose as described in Experimental Pro-
cedures. Bound eIF4E and associated 4EBP-1 were detected 
by Western blotting. (C) MCF7-4EBP-1-5A (left) or MCF-7 
(right) cells were grown in the presence (open circles) or 
absence (closed circles) of pon A. Cell numbers were 
counted on days 1, 3 and 5 as indicated. Each point repre-
sents the mean (± standard error) of either 4 (left panel) or 3 
(right panel) independent determinations of cell number.
Figure 2
Expression of 4EBP-1-5A enhances expression of 
p27Kip1 and inhibits expression of cyclin D1. (A) MCF7-
4EBP-1-5A cells were treated with or without pon A and 
harvested 1, 2 or 3 days after treatment for analysis of cellu-
lar proteins by Western blotting. Each lane represents pro-
teins from 2 × 105 cells. The same membrane was used to 
detect p27Kip1, cyclin D1, CDK2, CDK4 and β-actin. (B) 
MCF7-4EBP-1-5A (left) or MCF7-pERV3 (right) cells treated 
with ponA (gray bars) or left untreated (open bars) for 3 
days were analyzed as described in A. After Western blot-
ting, protein levels were estimated by densitometry and nor-
malized using β-actin as a standard.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/2
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or without pon A. Addition of pon A altered the levels of
two critical G1 regulatory proteins. There was a significant
increase in the level of p27Kip1 observed at every time
point up to three days after addition of pon A (Fig. 2A and
2B). At the same time there was a substantial decrease in
the level of cyclin D1. No difference was observed in the
protein levels of CDK4 or CDK2 between pon A treated
and untreated cells. Treatment of MCF7-pERV3 cells,
which express the ecdysone receptor/VP16 fusion protein
but not the inducible constitutively active 4EBP-1 (see
Methods), with pon A had no effect on the expression of
any of these proteins (Fig. 2B).
Constitutively active 4EBP-1 does not alter p27Kip1 and cy-
clin D1 turnover rates
The results above suggest that cell cycle arrest of MCF7
cells in response to 4EBP-1-5A expression involves specif-
ic effects on expression of cyclin D1 and p27Kip1. The
most plausible explanation is that the observed changes
are mediated by altered rates of translation. However, oth-
ers have shown that eIF4E overexpression enhances cyclin
D1 mRNA transport from the nucleus to the cytosol [25]
and it is possible that 4EBP-1 affects this process. Also,
p27Kip1  expression is actually enhanced while 4EBP-1
would be expected to inhibit translation rates. Therefore it
was of interest to examine the mechanism by which 4EBP-
1-5A expression modulates p27Kip1 and cyclin D1 levels.
First, to determine if 4EBP-1 led to a change in degrada-
tion of either p27Kip1 or cyclin D1, turnover rates were es-
timated in MCF7-4EBP-1-5A cells that had been treated
with or without pon A for 24 hours. Cycloheximide was
added for various times and p27Kip1 and cyclin D1 levels
were estimated by western blotting (Fig. 3). Neither the
rate of p27Kip1 turnover nor that of cyclin D1 was signifi-
cantly altered by pon A-induced expression of 4EBP-1-5A.
Thus, modulation of p27Kip1 and cyclin D1 levels in re-
sponse to expression of constitutively active 4EBP-1 does
not appear to be mediated by changes in protein
degradation.
Expression of constitutively active 4EBP-1 does not alter 
p27Kip1 mRNA levels but decreases cyclin D1 mRNA levels
To examine whether 4EBP-1 could regulate p27Kip1 or cy-
clin D1 at the transcriptional level or through changes in
message stability, the levels of p27Kip1  and cyclin D1
mRNA levels were examined by Northern blotting (Fig. 4A
and 4B) There was no difference in mRNA levels encoding
p27Kip1 after treatment with pon A. However, pon A treat-
ment led to an approximately 50% decrease in the levels
of cyclin D1 mRNA (Fig. 4B). This may contribute to the
downregulation of cyclin D1 protein and is consistent
with a previous report showing an increase in cyclin D1
mRNA in cells overexpressing eIF4E [26].
Expression of 4EBP-1-5A enhances de novo p27Kip1 pro-
tein synthesis
The observation that expression of constitutively active
4EBP-1 leads to increased p27Kip1, but does not signifi-
cantly affect protein turnover or mRNA levels suggests that
synthesis of p27Kip1 is affected. Therefore, the effect of
4EBP-1-5A on the de novo synthesis of p27Kip1 was tested
by metabolic labeling with [35S]-labeled amino acids. Af-
ter treatment of MCF7-4EBP-1-5A cells with or without
pon A for 48 hours the cells were pulse labeled for 1.5
hours. Half of the cellular extract was used to immunopre-
cipitate cyclin D1 and the other half to immunoprecipi-
tate p27Kip1 (Fig. 5A and 5B). The results demonstrate an
increase in p27Kip1 protein synthesis of approximately
two-fold in cells expressing 4EBP-1-5A. Since no changes
in p27Kip1  mRNA levels or protein turnover were ob-
served, the increased synthesis of p27Kip most likely re-
flects increased rates of translation. In the same
experiment a substantial decrease in de novo synthesis of
cyclin D1 was observed, which could be due, in part, to
lower cyclin D1 mRNA levels (see Fig. 4). Interestingly, to-
tal protein synthesis, as determined by trichloroacetic acid
(TCA) precipitation of total cellular proteins following
pulse labeling, was decreased only about 15% by expres-
sion of constitutively active 4EBP-1 (Fig. 5B). This is con-
sistent with reports that changes in the levels of active
Figure 3
Effect of constitutively active 4EBP-1 on turnover of 
p27Kip1 and cyclin D1. MCF7-4EBP-1-5A cells were cul-
tured in the presence (open circles) or absence (closed cir-
cles) of pon A for 24 hours at which time cycloheximide (100 
µg/ml) was added. At the indicated time cells were harvested 
for analysis of p27Kip1 (left) or cyclin D1 (right) protein levels 
by Western blotting. Protein levels were then estimated by 
densitometry.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/2
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eIF4E have a much greater effect on the translation of spe-
cific classes of mRNA than on general translation rates
[15,27].
Expression of 4EBP-1-5A leads to inhibition of CDK2 
activity
A critical factor in p27Kip1-mediated cell cycle arrest is in-
hibition of CDK2. 4EBP-1-5A expression did not signifi-
cantly change CDK2 protein levels (see Fig. 2A). However,
there was a substantial loss of CDK2 activity as
determined by an immunoprecipitation kinase assay (Fig.
6). This loss of CDK2 activity correlated with an increase
in the amount of p27Kip1 that co-immunoprecipitated
with CDK2 (Fig. 6). At the same time, the association of
p27Kip1 with CDK4 was dramatically decreased (Fig. 6).
These results suggest that 4EBP-dependent cell cycle arrest
involves p27Kip1-mediated inhibition of CDK2 kinase
activity.
Expression of constitutively active 4EBP-1-5A enhances 
cap-independent translation through the p27Kip1 5'-UTR
A novel finding of the experiments above is that synthesis
of endogenous p27Kip1 is enhanced under conditions that
are expected to reduce cap-dependent translation. One
possibility is that the p27Kip1 mRNA is translated through
a cap-independent mechanism that does not require
Figure 4
Effect of constitutively active 4EBP-1 on p27Kip1 and 
cyclin D1 mRNA levels. (A) MCF7-4EBP-1-5A cells were 
cultured with or without pon A for 2 days and then the levels 
of mRNA encoding p27Kip1 (top panel) or cyclin D1 (middle 
panel) were determined by Northern blotting. Total RNA 
was detected by staining the gel with Sybr Gold prior to 
transfer (bottom panel). (B) Densitometric quantitation of 
the Northern blot data shown in A. White bars denote RNA 
levels in the absence of pon A and black bars denote synthe-
sis in the presence of pon A.
Figure 5
Effect of constitutively active 4EBP-1 on synthesis 
p27Kip1 and cyclin D1. (A) MCF7-4EBP-1-5A cells were 
cultured with or without pon A for 2 days. The cells were 
then pulse-labeled for 1.5 hours with 35S-amino acids in the 
presence of the proteasome inhibitor MG-132 to limit degra-
dation of newly synthesized protein. Labeled cyclin D1 and 
p27Kip1 were immunoprecipitated, separated by SDS-PAGE, 
and detected by autoradiography. (B) The levels of newly 
synthesized p27Kip1 and cyclin D1, as detected in A, were 
estimated by densitometry. The level of total protein synthe-
sis was determined by TCA precipitation of a portion of the 
same extracts prior to immunoprecipitation.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/2
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eIF4E. It was recently demonstrated that elements within
a 217 nucleotide sequence from the 5'-UTR of the mouse
p27Kip1 mRNA is able to mediate cap-independent trans-
lation of a reporter gene in NIH3T3 and D6P2T cells [28].
There is a high level of sequence homology between the
mouse and human 5'-UTRs and the major transcriptional
start site is also conserved [29]. Therefore it is likely the 5'-
UTR of the human p27Kip1 message is also able to mediate
cap-independent translation initiation. To test this, a 472
nucleotide fragment, representing the full-length human
p27Kip1 5'-UTR derived from transcription initiation at
the major start site, was inserted into the bicistronic
expression vector pGL2CAT/Luc [30]. In this vector, the
first cistron, encoding chloramphenicol acetyltransferase
(CAT), is proximal to the mRNA's cap structure and there-
fore expected to be translated by the conventional cap-de-
pendent translation mode. The second cistron, encoding
luciferase, is downstream of the CAT stop codon and
therefore must be translated by a cap-independent mech-
anism mediated by sequence elements inserted between
the two cistrons. Bicistronic constructs without an insert
or with the human p27Kip1 5'-UTR inserted in either the
correct or reverse orientation were transiently expressed in
MCF7 cells. The cells were harvested after one day and
both CAT and luciferase activities were analyzed (Fig. 7A
and 7B). Expression of CAT was nearly identical with all
three constructs and was therefore independent of an in-
sert between the two coding regions. In contrast, only the
construct carrying the p27Kip1 5'-UTR insert in the correct
orientation expressed a significant level of luciferase. The
ratio of luciferase/CAT was enhanced approximately 12-
fold by the human 5'-UTR (Fig. 7B). Thus the full-length
human p27Kip1 5'-UTR is able to mediate cap-independ-
ent translation in a manner similar to that previously
shown for the 217 nucleotide sequence of the mouse 5'-
UTR [28].
The effect of constitutively active 4EBP-1 on the activity of
the p27Kip1 5'-UTR was determined by cotransfecting the
bicistronic construct together with an expression vector
encoding 4EBP-1-5A into MCF7 cells. Expression of 4EBP-
1-5A led to a two-fold increase in the luciferase/CAT ratio
(Fig. 7C). Interestingly, this is approximately the same lev-
el of increase that is observed in synthesis of endogenous
p27Kip1 protein (see Fig. 5B).
Discussion
In normal mitogen-activated cells eIF4E activity is en-
hanced due to elevated transcription of the eIF4E gene, a
phosphorylation-dependent increase in affinity for the 7-
methylguanosine cap, and phosphorylation-dependent
inactivation of the inhibitor protein 4EBP. In many tumor
cells eIF4E levels are elevated and overexpression of the
protein in normal cultured cells causes transformation. El-
evated eIF4E levels enhance translation of specific mR-
NAs. Many of these mRNAs are involved in cell cycle
progression. They have long GC-rich 5'-UTRs that can
form extensive secondary structure and have been classi-
fied as "weak" mRNAs because they are translated ineffi-
ciently when eIF4E levels are limiting (reviewed in [15]).
It has been proposed that when eIF4E levels are elevated
these mRNAs can more effectively recruit eIF4E and its as-
sociated factors including eIF4G, a scaffold protein essen-
tial in recruiting the small ribosomal subunit, and eIF4A,
a helicase essential for scanning through secondary struc-
tures in the 5'-UTR [15,27].
In the experiments described here we have inducibly ex-
pressed a constitutively active form of 4EBP-1 in the hu-
man breast cancer cell line MCF7. This leads to nearly
complete inhibition of cell proliferation which is associat-
ed with an increase in binding of 4EBP-1 to eIF4E. This
does not lead to a major drop in total protein synthesis as
indicated by metabolic labeling with 35S-amino acids.
However, there are major changes in expression of two
cell cycle regulatory proteins, cyclin D1 and p27Kip1. Cyc-
lin D1 levels decline to about 30% of that observed in
uninduced cells and this appears to be due to a reduction
in cyclin D1 mRNA levels and protein synthesis, since
there was no evidence for changes in cyclin D1 turnover.
The observed decline in cyclin D1 is expected since consti-
tutively active 4EBP should reverse cyclin D1 expression
mediated by eIF4E overexpression. Interestingly, others
have demonstrated that eIF4E has an additional role in
the nucleus. A portion of the cellular eIF4E is imported
into the nucleus through a mechanism that requires the
protein 4E-T [31]. In the nucleus eIF4E is localized to spe-
cific nuclear bodies and associates with promyelocytic
leukemia protein (PML, [32]). Nuclear eIF4E appears to
be involved in export of cyclin D1 mRNA to the cytosol
[25]. Both 4E-T and PML interact with the same domain
of eIF4E that binds 4EBP [32]. Thus expression of
constitutively active 4EBP may block nuclear functions of
eIF4E, one consequence being a reduction in cyclin D1
mRNA that can be translated in the cytoplasm.
In contrast to cyclin D1, p27Kip1 levels increase when
4EBP-1-5A is expressed. An interesting note is that the
p27Kip1 mRNA has a long 5'-UTR that is 65% GC and is
predicted to form stable secondary structures [29]. Thus,
even though it shares these characteristics with the
putative "weak" mRNAs that require elevated eIF4E activ-
ity for efficient translation, p27Kip1 responds in an oppo-
site manner. Part of this can be explained by the fact that
the p27Kip1 5'-UTR is able to promote cap-independent
translation. When placed between the CAT and luciferase
coding regions in a bicistronic mRNA, the 5'-UTR stimu-
lates high level expression of the downstream coding re-
gion (luciferase). This property is shared by the highly
homologous mouse p27Kip1 5'-UTR [28]. Coexpression ofCancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/2
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4EBP-1-5A with the bicistronic construct containing the
p27Kip1 5'-UTR leads to an approximately two-fold in-
crease in cap-independent expression. This increase is
similar to that observed for endogenous p27Kip1 in cells
induced to express 4EBP-1-5A. The mechanism by which
4EBP-1-5A could mediate enhanced translation through
the p27Kip1 5'-UTR is not presently known. One possibil-
ity is that binding of 4EBP-1 to eIF4E releases other
initiation factors that are in limited supply but also re-
quired for cap-independent initiation.
Inhibition of cell proliferation by 4EBP-1-5A correlates
with a large decrease in CDK2 activity. This is not due to a
decline in CDK2 or cyclin E protein levels. Rather it corre-
sponds to enhanced binding of p27Kip1 to the cyclin E/
CDK2 complex. This is probably mediated by two sepa-
rate mechanisms. First, downregulation of cyclin D1 leads
to release of p27Kip1 sequestered by the cyclin D1/CDK4
complex. This is indicated by a large decrease in co-immu-
noprecipitation of p27Kip1 with CDK4 upon induction of
4EBP-1-5A. Second, de novo synthesis contributes to the
pool of cellular p27Kip1 that is available to bind the cyclin
E/CDK2 complex.
Given its role in control of cell proliferation and in tum-
origenesis, there is interest in targeting the pathways that
control eIF4E activity for cancer chemotherapy. Clinical
trials using the rapamycin analog CCI-779 show promise
for this strategy [22]. Rapamycin and its synthetic analogs
block mTOR kinase activity leading to dephosphorylation
of 4EBP and other mTOR substrates. MCF7 cells are sensi-
tive to rapamycin analogs in the low nM range [33]. A po-
tential problem with the use of rapamycin and its analogs
is that some tumors are intrinsically resistant to its effects
[33,34]. Resistance in mammalian cells has been associat-
ed with decreased expression of 4EBP-1 [35], mutations in
the ATM protein [36], and low level expression of p27Kip1
due to enhanced turnover of the protein [37]. In addition,
it has been demonstrated that fibroblasts from p27Kip1
knockout mice are more resistant to the effects of rapamy-
cin than normal cells [37]. Thus p27Kip1 is an important
mediator of cell growth inhibition in response to rapamy-
cin. Many tumor cells express very low levels of p27Kip1
and this is correlated with poor prognosis. If rapamycin
and its analogs are to be developed as useful antitumor
agents, it will be important to determine how p27Kip1 lev-
els affect responsiveness to these compounds.
Rapamycin and its analogs affect all of the downstream
targets of mTOR, including p70 S6 kinase and other com-
ponents of the translation machinery. The data presented
here indicate that direct inhibition of eIF4E may be more
effective and a more specific means of targeting tumor
cells than treatment with rapamycin. It will be important
to determine if direct inhibition of eIF4E is able to arrest
the cell cycle in rapamycin resistant tumors. If so, it may
be possible to develop reagents that target eIF4E activity,
thereby bypassing the upstream signaling events in the
pathway.
Methods
Cell culture
MCF7 cells were cultured in Dulbecco's modified Eagle's
medium (DMEM) supplemented with 10% fetal calf se-
rum (FCS), 100 U/ml penicillin, and 100 µg/ml strepto-
mycin. The inducible MCF7 cell line expressing 4EBP-1-
5A was established using the Complete Control™ Induci-
ble Mammalian Expression System (Stratagene). First,
MCF7 cells were transfected with the pERV3 vector encod-
ing both the RXR protein and an ecdysone/glucocorticoid
receptor fusion protein using GenePorter (Gene Therapy
Systems). Stably transfected colonies were selected using
G418 (400 µg/ml). These colonies were further screened
for the ability to inducibly express luciferase from the
pEGSH-luc construct in response to pon A in transient
transfection assays. A responsive cell line derived in this
manner (designated MCF7-pERV3) was further transfect-
ed with pEGSH-4EBP-1-5A, a construct in which a consti-
tutively active form of 4EBP-1 is inserted into the pon A-
inducible expression cassette of pEGSH. Cell clones were
selected using hygromycin B (100 µg/ml). The resulting
colonies were isolated, expanded, and tested for pon A-in-
ducible expression of 4EBP-1-5A. A single stably transfect-
ed cell line designated MCF7-4EBP-1-5A was used in the
experiments described.
Transfections and reporter assays
Cells growing in 35 mm plates were transfected using
GenePorter. One day after transfection cells were lysed us-
ing reporter lysis buffer (Promega) and scraped from the
dishes. Luciferase activity was determined using the
Steady-Glo substrate (Promega) according to the
manufacturer's protocol, using 50 µl of cellular extract.
CAT enzyme activity was determined using 14C-labeled
chloramphenicol as described previously [38].
Plasmid constructs
The human p27Kip1 5'UTR was amplified by PCR using
primers CCCAAGCTTTCTCCCGGGTCTGCACGAC-
CGCCTCT and CCCAAGCTTCTTCGTCAGCCTCCCTTC-
CAC. The PCR product was digested with Hind III and
ligated into the Hind III site of pGL2CAT/Luc (a gift of
R.E. Rhoads). To subclone 4EBP-1-5A into pEGSH the
plasmid pcDNA3.1-4EBP-1-5A was digested with Hind
III, the ends were filled using Klenow fragment, and then
the insert was released by digesting with Xba I. The result-
ing fragment was ligated into pEGSH that had been digest-
ed with Eco RV and Xba I.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/2
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Cell proliferation assay
MCF7 and MCF7-4EBP-1-5A cells were treated with pon A
(10 µM) or the same volume of ethanol for 5 days. The
medium was changed every day. After 1, 3, or 5 days incu-
bation, cells were harvested using trypsin and the cell
number was determined using a hemacytometer.
Western blotting
Cells were harvested by trypsinization and the cell
number was determined using a hemacytometer. The cells
were pelleted and washed with phosphate-buffered saline
(PBS). The cell pellets were resuspended in sodium do-
decylsulfate (SDS)-sample buffer at 1 × 104 cells per µl
and then sonicated to shear nucleic acids. Samples repre-
senting 2 × 105 cells were separated by SDS-polyacryla-
mide gel electrophoresis (SDS-PAGE) and transferred to
Immobilion P membranes. Membranes were probed with
the appropriate antibodies. The p27Kip1 and eIF4E mono-
clonal antibodies were purchased from Transduction
Laboratories. Anti-PHAS1 (4EBP-1) polyclonal antibody
was purchased from Zymed. Anti-β-actin monoclonal an-
tibody was purchased from Sigma. Antibodies against cy-
clin D1, CDK2, and CDK4 were purchased from Santa
Cruz Biotechnology. Secondary horseradish peroxidase-
linked anti-mouse or anti-rabbit IgG antibodies were pur-
chased from Santa Cruz Biotechnology. Bands were visu-
alized using the SuperSignal West Pico
chemiluminescence detection system (Pierce).
Protein turnover analysis
MCF7-4EBP-1-5A cells were cultured in the presence or
absence of pon A (10 µM) for 24 hours. The medium was
then changed with readdition of pon A or an equal vol-
ume of ethanol and the protein synthesis inhibitor cy-
cloheximide (100 µg/ml, Sigma) was added. Cells were
incubated for the indicated times and then harvested in
SDS-sample buffer as described above for Western blot-
ting. Cyclin D1 and p27Kip1 proteins were detected by
Western blotting and the levels of each protein were
estimated by densitometry using a ChemiImager system
(Alpha Innotech).
Cap-binding assay
MCF7-4EBP-1-5A cells were cultured in the presence or
absence of pon A (10 mM) for 48 hours. Cell monolayers
were washed with PBS three times and then lysed in lysis
buffer (50 mM Tris-HCl, pH 7.5, 150 mM KCl, 1 mM
dithiothreitol, 1 mM EDTA, 10 µg/ml leupeptin, 2 µg/ml
Aprotinin, and 0.1 mM PMSF) by subjecting the cells to 3
cycles of freezing in liquid nitrogen and thawing in a
37°C water bath. The lysate was then centrifuged at full
speed in a microcentrifuge at 4°C for 15 min. The super-
natants were incubated with 50 µl of 7-methyl-GTP-
Sepharose (Amersham Pharmacia Biotech, Inc.) at 4°C
for 2 hours on a rotator. The resin was washed three times
with lysis buffer and resuspended in 50 µl of SDS-sample
buffer. Proteins were resolved by SDS-PAGE and trans-
ferred to Immobilon P membranes. eIF4E and 4EBP-1
were detected by Western blotting.
Immunoprecipitation, pulse-labeling and CDK2 kinase 
assays
Cell extracts were prepared using a lysis buffer consisting
of 50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA,
2.5 mM EGTA, 10% glycerol, 0.1% Tween-20, 1 mM DTT,
1 mM NaF, 0.1 mM Na3VO4, 10 µg/ml leupeptin, 2 µg/ml
Aprotinin, and 0.1 mM PMSF. Extracts were briefly soni-
cated and then centrifuged at full speed in a microcentri-
fuge at 4°C for 15 min. Protein concentration was
determined using the Bio-Rad protein assay solution.
For pulse-labeling, the cells were washed three times with
DMEM lacking Met and Cys and then incubated in the
same medium containing 80 µCi/ml of 35S-labeled Met
and Cys (Tran35S-label, ICN) and the proteasome inhibi-
tor MG-132 (10 µM, Calbiochem) for 1.5 hours. The cells
were washed three times with ice-cold PBS and lysed as
above. A portion of the supernatant was precipitated with
TCA to estimate the level of total protein synthesis. The re-
Figure 6
Effect of constitutively active 4EBP-1 on p27Kip1 asso-
ciation with CDK2 and CDK4. MCF7-4EBP-1-5A cells 
were cultured with or without pon A for 2 days. Cell 
extracts were prepared as described in Experimental Proce-
dures. A portion of each extract, containing equal amounts of 
protein, was subjected to immunoprecipitation with anti-
CDK2 (left) or anti-CDK4 (right) antibodies. After immuno-
precipitation a portion of the sample was used to detect 
p27Kip1 and CDK2 by Western blotting. For the CDK2 
immunoprecipitate the remainder of the precipitate was used 
to assay CDK2 kinase activity with histone H1 as a substrate.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/2
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mainder of the cell extract was used for immunoprecipita-
tion. Equal amounts of total protein from each extract
(0.5 to 1 mg) were used for analysis. Cell lysates were in-
cubated with 2 µg of rabbit polyclonal antibody overnight
at 4°C on a rotator. Protein A-conjugated agarose beads
(30 µl) were added, and the incubation continued for 1
hour on a rotator. The beads were pelleted and washed
five times with lysis buffer. Next, 30 µl of 2X SDS-sample
buffer was added to elute immunoprecipitated proteins.
Labeled proteins were resolved by SDS-PAGE and detect-
ed by autoradiography.
For CDK2 kinase assays, lysates (100 µg protein) prepared
as described above were used to immunoprecipitate
CDK2 with a polyclonal antibody. The beads with the
bound proteins were washed and then resuspended in 30
µl of kinase buffer [50 mM HEPES, pH 7.4, 2.5 mM EGTA,
10 mM β-glycerophosphate, 0.1 mM vanadate, 1 mM
NaF, 1 mM DTT, 10 mM MgCl2, 20 µM ATP, 50 µCi γ-32P-
ATP (7000 Ci/mmol, ICN), and 1 µg histone H1]. Reac-
tion mixtures were incubated for 15 min at 30°C and
stopped by adding the same volume of 2X SDS-sample
buffer. The phosphorylated histone H1 was resolved by
SDS-PAGE and detected by autoradiography using Kodak
XAR-5 film.
For co-immunoprecipitation of p27Kip1 with CDK4 or
CDK2, immunoprecipitations were performed as de-
scribed above with either anti-CDK4 or anti-CDK2. The
precipitated proteins were dissolved in SDS-sample
buffer, separated by SDS-PAGE and then p27Kip1  and
CDK2 were detected by Western blotting.
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